BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38290900)

  • 1. The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer.
    Sung D; Schmidt B; Tward JD
    Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort.
    Würnschimmel C; Pose RM; Wenzel M; Tian Z; Incesu RB; Karakiewicz P; Graefen M; Tilki D
    Eur Urol; 2021 Oct; 80(4):400-404. PubMed ID: 34162491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.
    Dess RT; Suresh K; Zelefsky MJ; Freedland SJ; Mahal BA; Cooperberg MR; Davis BJ; Horwitz EM; Terris MK; Amling CL; Aronson WJ; Kane CJ; Jackson WC; Hearn JWD; Deville C; DeWeese TL; Greco S; McNutt TR; Song DY; Sun Y; Mehra R; Kaffenberger SD; Morgan TM; Nguyen PL; Feng FY; Sharma V; Tran PT; Stish BJ; Pisansky TM; Zaorsky NG; Moraes FY; Berlin A; Finelli A; Fossati N; Gandaglia G; Briganti A; Carroll PR; Karnes RJ; Kattan MW; Schipper MJ; Spratt DE
    JAMA Oncol; 2020 Dec; 6(12):1912-1920. PubMed ID: 33090219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
    Kishan AU; Shaikh T; Wang PC; Reiter RE; Said J; Raghavan G; Nickols NG; Aronson WJ; Sadeghi A; Kamrava M; Demanes DJ; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    Eur Urol; 2017 May; 71(5):766-773. PubMed ID: 27452951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
    Cooperberg MR; Broering JM; Carroll PR
    J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
    JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
    Freedland SJ; Choeurng V; Howard L; De Hoedt A; du Plessis M; Yousefi K; Lam LL; Buerki C; Ra S; Robbins B; Trabulsi EJ; Shah NL; Abdollah F; Feng FY; Davicioni E; Dicker AP; Karnes RJ; Den RB
    Eur Urol; 2016 Oct; 70(4):588-596. PubMed ID: 26806658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of prostate carcinoma death in patients with lymph node metastasis.
    Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
    Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
    Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy.
    Dariane C; Taussky D; Delouya G; Wenzel M; Karakiewicz P; Saad F; Würnschimmel C
    World J Urol; 2021 Nov; 39(11):4127-4133. PubMed ID: 34052878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
    Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
    Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study.
    Castelli T; Russo GI; Favilla V; Urzi D; Spitaleri F; Reale G; Giardina R; Saita A; Madonia M; Cimino S; Morgia G
    Int Braz J Urol; 2014; 40(3):322-9. PubMed ID: 25010298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.
    Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW
    BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
    Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer.
    Reyes DK; Rowe SP; Schaeffer EM; Allaf ME; Ross AE; Pavlovich CP; Deville C; Tran PT; Pienta KJ
    Med Oncol; 2020 Jun; 37(7):60. PubMed ID: 32524295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.